Dr. Chul Kim
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 19
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 162
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
DC license MD044812 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Medstar Washington Hospital Center Washington, DC
- Medstar Georgetown University Hospital Washington, DC
Medical groups
- Medstar Medical Group II LLC (3,767 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 162
- Services billed
- 787
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 296 | 78 |
| Established patient office or other outpatient visit, 30-39 minutes | 119 | 47 |
| New patient office or other outpatient visit, 60-74 minutes | 31 | 31 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 28 | 18 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 18 | 14 |
| Established patient office or other outpatient visit, 20-29 minutes | 16 | 13 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tagrisso (osimertinib mesylate) | 57 |
| Prednisone Other prescribers in Washington, DC | 50 |
| Oxycodone Hcl Other prescribers in Washington, DC | 46 |
| Eliquis (apixaban) Other prescribers in Washington, DC | 39 |
| Ondansetron Hcl Other prescribers in Washington, DC | 37 |
| Gabapentin Other prescribers in Washington, DC | 31 |
| Dexamethasone Other prescribers in Washington, DC | 26 |
| Hydrocortisone Other prescribers in Washington, DC | 23 |
| Erlotinib Hcl | 22 |
| Mirtazapine Other prescribers in Washington, DC | 21 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 14 companies reported 72 payments worth $64,694 in total to this clinician.
| Boehringer Ingelheim International GmbH | $12,583 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $10,724 |
| Janssen Biotech, Inc. | $9,425 |
| Regeneron Pharmaceuticals, Inc. | $7,274 |
| E.r. Squibb & Sons, L.l.c. | $5,830 |
| Partner Therapeutics, Inc. | $4,418 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $3,783 |
| Takeda Pharmaceuticals U.S.A., Inc. | $3,500 |
| Consulting Fee | $59,790 |
|---|---|
| Travel and Lodging | $2,955 |
| Food and Beverage | $1,949 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Boehringer Ingelheim International GmbH Mar 6, 2025 | Consulting Fee | $8,800 |
| E.r. Squibb & Sons, L.l.c. Nov 19, 2025 | Consulting Fee | $5,730 |
| Janssen Biotech, Inc. May 27, 2025 | Consulting Fee RYBREVANT · Oncology | $4,688 |
| Regeneron Pharmaceuticals, Inc. Feb 21, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $4,613 |
| AstraZeneca Pharmaceuticals LP Nov 23, 2025 | Consulting Fee | $4,510 |
| Takeda Pharmaceuticals U.S.A., Inc. Mar 26, 2025 | Consulting Fee ALUNBRIG · ONCOLOGY | $3,500 |
| EMD Serono, Inc. Jul 11, 2025 | Consulting FeeCompany’s descriptionAdvisory Board Participation (Fee For Service) | $3,325 |
| AstraZeneca Pharmaceuticals LP Aug 27, 2025 | Consulting Fee | $3,280 |
| Partner Therapeutics, Inc. Mar 6, 2025 | Consulting Fee Bizengri · Hematology/Oncology | $3,000 |
| Regeneron Pharmaceuticals, Inc. Feb 21, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $2,636 |
All 41 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Nov 25, 2025 | Consulting Fee RYBREVANT · Oncology | $1,670 |
| AstraZeneca Pharmaceuticals LP Nov 23, 2025 | Consulting Fee | $4,510 |
| AstraZeneca Pharmaceuticals LP Nov 23, 2025 | Travel and Lodging travel to Philadelphia, PA Company’s descriptionConsulting Expenses | $20.19 |
| E.r. Squibb & Sons, L.l.c. Nov 19, 2025 | Consulting Fee | $5,730 |
| AstraZeneca Pharmaceuticals LP Nov 12, 2025 | Travel and Lodging travel to Philadelphia, PA · in-kind Company’s descriptionConsulting Expenses | $40.84 |
| AstraZeneca Pharmaceuticals LP Nov 12, 2025 | Travel and Lodging travel to Philadelphia, PA · in-kind Company’s descriptionConsulting Expenses | $37.55 |
| AstraZeneca Pharmaceuticals LP Nov 12, 2025 | Travel and Lodging travel to Philadelphia, PA · in-kind Company’s descriptionConsulting Expenses | $34.02 |
| AstraZeneca Pharmaceuticals LP Nov 12, 2025 | Travel and Lodging travel to Philadelphia, PA · in-kind Company’s descriptionConsulting Expenses | $33.62 |
| AstraZeneca Pharmaceuticals LP Nov 12, 2025 | Travel and Lodging travel to Philadelphia, PA · in-kind Company’s descriptionConsulting Expenses | $16.04 |
| Bayer HealthCare Pharmaceuticals Inc. Oct 10, 2025 | Consulting Fee | $685 |
| AstraZeneca Pharmaceuticals LP Sep 18, 2025 | Consulting Fee TAGRISSO · Oncology | $2,050 |
| AstraZeneca Pharmaceuticals LP Aug 27, 2025 | Consulting Fee | $3,280 |
| Boehringer Ingelheim International GmbH Jul 21, 2025 | Consulting Fee | $1,480 |
| EMD Serono, Inc. Jul 11, 2025 | Consulting FeeCompany’s descriptionAdvisory Board Participation (Fee For Service) | $3,325 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 8, 2025 | Consulting Fee | $1,370 |
| Janssen Biotech, Inc. Jul 7, 2025 | Consulting Fee RYBREVANT · Oncology | $1,500 |
| Pfizer Inc. Jul 2, 2025 | Consulting Fee | $1,300 |
| Janssen Biotech, Inc. May 27, 2025 | Consulting Fee RYBREVANT · Oncology | $4,688 |
| Janssen Biotech, Inc. May 27, 2025 | Travel and Lodging RYBREVANT · Oncology · travel to GRAPEVINE, TX | $222 |
| Janssen Biotech, Inc. May 27, 2025 | Travel and Lodging RYBREVANT · Oncology · travel to GRAPEVINE, TX | $73.59 |
| Janssen Biotech, Inc. May 27, 2025 | Travel and Lodging RYBREVANT · Oncology · travel to GRAPEVINE, TX | $61.23 |
| Janssen Biotech, Inc. May 10, 2025 | Travel and Lodging RYBREVANT · Oncology · travel to GRAPEVINE, TX · in-kind | $391 |
| Janssen Biotech, Inc. May 10, 2025 | Travel and Lodging RYBREVANT · Oncology · travel to GRAPEVINE, TX · in-kind | $114 |
| Janssen Biotech, Inc. May 9, 2025 | Travel and Lodging RYBREVANT · Oncology · travel to GRAPEVINE, TX · in-kind | $338 |
| Janssen Biotech, Inc. May 9, 2025 | Travel and Lodging RYBREVANT · Oncology · travel to GRAPEVINE, TX · in-kind | $114 |
| Takeda Pharmaceuticals U.S.A., Inc. Mar 26, 2025 | Consulting Fee ALUNBRIG · ONCOLOGY | $3,500 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Mar 25, 2025 | Consulting Fee | $2,220 |
| Boehringer Ingelheim International GmbH Mar 6, 2025 | Consulting Fee | $8,800 |
| Partner Therapeutics, Inc. Mar 6, 2025 | Consulting Fee Bizengri · Hematology/Oncology | $3,000 |
| Partner Therapeutics, Inc. Mar 6, 2025 | Travel and Lodging Bizengri · Hematology/Oncology · travel to New Orleans, LA | $169 |
| Boehringer Ingelheim International GmbH Mar 6, 2025 | Consulting Fee | $89.32 |
| Partner Therapeutics, Inc. Mar 6, 2025 | Travel and Lodging Bizengri · Hematology/Oncology · travel to New Orleans, LA | $56.06 |
| Boehringer Ingelheim International GmbH Mar 6, 2025 | Travel and Lodging travel to Dulles, VA · in-kind | $52.02 |
| Boehringer Ingelheim International GmbH Mar 6, 2025 | Consulting Fee | $13.69 |
| Boehringer Ingelheim International GmbH Mar 3, 2025 | Consulting Fee | $1,850 |
| Regeneron Pharmaceuticals, Inc. Feb 21, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $4,613 |
| Regeneron Pharmaceuticals, Inc. Feb 21, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $2,636 |
| Partner Therapeutics, Inc. Feb 13, 2025 | Travel and Lodging Bizengri · Hematology/Oncology · travel to New Orleans, LA | $534 |
| Partner Therapeutics, Inc. Feb 13, 2025 | Travel and Lodging Bizengri · Hematology/Oncology · travel to New Orleans, LA · in-kind | $467 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Jan 29, 2025 | Consulting Fee | $1,480 |
| Boehringer Ingelheim International GmbH Jan 22, 2025 | Travel and Lodging travel to Frankfurt, Germany · in-kind | $182 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 13 industry-funded studies in 2025, from 9 companies. The companies reported $3,915,968 in research payments for these studies, mostly to the institutions running them.
- Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations
Boehringer Ingelheim Pharma GmbH & Co.kg - HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer
Daiichi Sankyo Inc. · Active, not recruiting · NCT04676477 - Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations
Boehringer Ingelheim Pharmaceuticals, Inc. - Title not available in IMPACT or MLCS
AstraZeneca Pharmaceuticals LP - A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line T…
Janssen Research & Development, LLC - A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line T…
Janssen Research & Development, LLC - DAREON-9: A Phase Ib open-label dose escalation and dose confirmation safety study of intravenous BI 764532 in combination with a single agent chemotherapy for the treatment of patients with relapsed/refractory small …
Boehringer Ingelheim Pharmaceuticals, Inc. - A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT04077099 - Phase I FIH study of BI 1810631
Boehringer Ingelheim Pharmaceuticals, Inc. - NAUTIKA1 previously LCMC4
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.